- Home
- BQ vs SILO Comparison
BQ vs SILO Comparison
Compare BQ & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BQ
- SILO
- Stock Information
- Founded
- BQ 2008
- SILO 2010
- Country
- BQ China
- SILO United States
- Employees
- BQ N/A
- SILO N/A
- Industry
- BQ Other Specialty Stores
- SILO Apparel
- Sector
- BQ Consumer Discretionary
- SILO Consumer Discretionary
- Exchange
- BQ Nasdaq
- SILO Nasdaq
- Market Cap
- BQ 7.1M
- SILO 5.9M
- IPO Year
- BQ 2020
- SILO N/A
- Fundamental
- Price
- BQ $3.30
- SILO $0.70
- Analyst Decision
- BQ
- SILO
- Analyst Count
- BQ 0
- SILO 0
- Target Price
- BQ N/A
- SILO N/A
- AVG Volume (30 Days)
- BQ 39.8K
- SILO 941.5K
- Earning Date
- BQ 10-28-2025
- SILO 11-11-2025
- Dividend Yield
- BQ N/A
- SILO N/A
- EPS Growth
- BQ N/A
- SILO N/A
- EPS
- BQ N/A
- SILO N/A
- Revenue
- BQ $64,617,102.00
- SILO $72,102.00
- Revenue This Year
- BQ N/A
- SILO $1.86
- Revenue Next Year
- BQ N/A
- SILO N/A
- P/E Ratio
- BQ N/A
- SILO N/A
- Revenue Growth
- BQ N/A
- SILO N/A
- 52 Week Low
- BQ $1.62
- SILO $0.41
- 52 Week High
- BQ $9.89
- SILO $3.37
- Technical
- Relative Strength Index (RSI)
- BQ 57.55
- SILO 54.08
- Support Level
- BQ $2.88
- SILO $0.58
- Resistance Level
- BQ $3.86
- SILO $0.83
- Average True Range (ATR)
- BQ 0.36
- SILO 0.05
- MACD
- BQ 0.01
- SILO 0.01
- Stochastic Oscillator
- BQ 52.94
- SILO 48.39
About BQ Boqii Holding Limited representing
Boqii Holding Ltd operates in the business of selling pet products through online stores. The store provides pet foods, health products, pet grooming products, pet bathing products, pet toys, fish tank, aquatic fertilizer, temperature control equipment, oxygen pump and other related products. Also, the company sells its products through offline channels to pet stores and hospitals.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.